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l . lntroducfion 
Leu- and Met-enkephalin, originally sequenced and 
synthesized [1], have many of the same biological 
activities as morphine. Enkephalins, for example, 
inhibit contractions ofmouse vas deferens and guinea 
pig ileum [1], inhibit binding of [3H]naloxone to ral 
brain [2] and induce analgesia when administered 
centrally to rats [3]. However, studies with enke- 
phalins have been hampered to date by their low 
potency and inability to induce analgesia when 
administered peripherally. Numerous analogs have 
been synthesized in an attempt to find a potent, 
peripherally active peptide. Several investigators have 
recently reported analogs that fulfill these require- 
ments: D-Met 2, ProS-enkephalinamide [4] and D-AIa 2 , 
D-LeuS-enkephalinamide [5].
The ability of morphine to release prolactin and 
growth hormone has been well documented [6,7] ; 
similarly, we found MetS-enkephalin able to release 
prolactin when administered ither s.c. or i.v. in high 
doses [8]. D-Ala2,D-LeuS-enkephalin was found to 
release both growth ormone and prolactin when given 
i.v., also in high doses [9]. The present report discusses 
D-Ala2,D-LeuS.enkephalinamide, pr viously shown to 
be a potent systemically active analgesic in rats, and 
now found to be more active than morphine in its 
ability to release growth hormone. These effects are 
completely inhibited by naloxone and partially 
blocked by somatostatin. 
2. Materials and methods 
2.1. Synthesis of peptide 
The synthesis of D-Ala 2,D-Leus-enkephalinamide, 
employing solid phase methodology, was as in [5]. 
2.2. Biological testing 
Male Charles River CD rats were injected sub- 
cutaneously with either D-Ala 2,D-Leu s-enkephalin- 
amide, morphine sulfate (Merck, Sharp and Dohme, 
West Point, PA) or saline. After 15 min the animals 
were decapitated and blood collected in Trasylol 
EDTA (12 mg EDTA and 6000 units Trasylol/6 ml 
blood). The same procedure was employed for studies 
with combinations of naloxone or somatostatin a d 
the enkephalin analog. Each plasma sample was 
assayed intriplicate for prolactin and growth hormone 
using NIAMDD reagents. The procedure [10] was 
employed for prolactin determinations and the 
procedure [11] for growth hormone. 
3. Results and discussion 
A stimulation of growth hormone release after 
administration f D-Ala2,D-LeuS-enkephalinamide is 
apparent at subcutaneous doses as low as 50/ag/kg 
(fig. 1) while morphine sulfate releases growth ormone 
at 200/ag/kg, but not at 50/ag/kg. Significant 
increases in plasma prolactin levels were observed 
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Fig. 1. Effect of various doses of D-Ala: ,D-Leu s-enkephalin- 
amide on growth hormone and prolactin secretion i  male rats. 
Each bar represents the mean + SEM for groups of eight rats. 
+p < 0.05; * p < 0.01 by analysis of variance. 
only at an enkephalin analog dose of 1 mg/kg (fig.l); 
morphine sulfate did not release prolactin at either 
of the levels studied. The release of both growth 
hormone and prolactin by a maximal (but not supra- 
maximal) dose of the enkephalin analog was com- 
pletely blocked by concomitant administration f 
naloxone (table 1), a result in agreement with reports 
of naloxone reversal of opioid peptide stimulated 
hormone release [6]. Somatostatin failed to inhibit 
analog-stimulated growth hormone and prolactin 
release. This result was surprising since complete 
inhibition was found [ 12] of pentobarbital-stimulated 
growth hormone release with this level of somato- 
statin. Additionally, growth hormone release was 
stimulated [ 13 ] by a combination ofsodium thiamylal 
and morphine was maximally blocked by 25/ag/kg 
somatostatin a d morphine-stimulated growth hor- 
mone release was blocked [14] by 200/ag/kg somato- 
statin. The failure ofsomatostatin o lower stimulated 
growth hormone levels in the present study suggests 
that D-AIa 2,D-Leu s-enkephalinamide may bring about 
growth hormone release via a pathway independent 
of the morphine or pentobarbital pathway. 
The analgesic potency of D-AIa 2 J)-Leu s- 
enkephalinamide was reported to be approx. 25% 
that of morphine sulfate after intravenous administra- 
tion. The present results (fig.l) indicate a2-fold 
increase in growth hormone releasing potency of this 
peptide as compared to morphine sulfate. This marked 
separation of activities is not equivalent for all hor- 
monal release, since peptide-induced prolactin release 
was observed only at 1.0 mg/kg, the same dose as 
reported for morphine-stimulated prolactin release in 
rats [6]. Previous work has suggested that other 
opioid peptides how a separation of activities, pro- 
lactin release being favored over growth hormone 
release. At the dose of MetS-enkephalin we employed 
to release prolactin [8], no plasma growth hormone 
elevation was observed (unpublished observations). 
A similar preferential release of prolactin has been 
reported after intracerebral dministration f 
/3-endorphin [ 15 ]. D-Ala 2 ,D-Leu S.enkephalinamide 
thus differs from the above peptides and morphine in 
its ability to release growth ormone at unusually low 
doses. 
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Table 1 
Treatment Growth ormone Prolaetin 
(ng/ml) (ng/ml) 
Control 
D-AIa 2 ,D-LeuS-Enkephalinamide, 1 mg/kg 
+ Naloxone, 200 pg/kg 
+ Somatostatin, 50pg/kg 
216 +- 87 22 ± 3 
610 +- 93 a 45 ± 7 a 
203 -+ 91 12 -+ 2 
490± 124 39±4 
ap < 0.01 
8 animals/group 
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